Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Eptifibatide facilitated PCI · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Eptifibatide facilitated PCI | DRUG | - |
Inclusion Criteria: * Ischemic chest discomfort of 30 minutes duration * Onset of chest pain 12 hours prior to entry into the study * ST segment elevation of \> 1 mm (0.1 mV) in two or more contiguous electrocardiographic leads (on a standard 12 lead electrocardiogram \[ECG\]), or left bundle branc...
Eptifibatide facilitated PCI is used for the treatment of myocardial infarction, commonly known as a heart attack. It is administered in the context of primary percutaneous coronary intervention, a procedure to open blocked coronary arteries. The drug is being studied to evaluate its safety and efficacy in this setting.
Eptifibatide facilitated PCI is developed by Medtronic plc, a medical technology company. Medtronic is publicly traded on the New York Stock Exchange under the ticker symbol MDT. The company is conducting clinical research to evaluate this treatment for myocardial infarction.
Eptifibatide facilitated PCI is in Phase 3 clinical development. It is an investigational therapy for myocardial infarction and has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the drug remains under evaluation for its safety and efficacy.
Eptifibatide facilitated PCI has one completed Phase 3 clinical trial registered under NCT00251823. The trial, titled "Safety and Efficacy Study of Eptifibatide in Primary Percutaneous Coronary Intervention (PCI)," enrolled 400 participants with myocardial infarction in Canada. The study was not blinded and did not use a control group.
The Phase 3 clinical trial of Eptifibatide facilitated PCI was randomized, meaning participants were assigned to treatment groups by chance. However, the trial was not double-blind and did not use a control group. The study enrolled 400 participants and has been completed.